Topic outline

  • General

    • Certificate issue 修了証発行
      Restricted Not available unless:
      • The activity questionnaire_01 is marked complete
      • The activity questionnaire_02 is marked complete
      • The activity questionnaire_03 is marked complete
      • The activity questionnaire_04 is marked complete

  • Precision Treatment and Translational Data Integration for Sarcomas and Rare Cancers | ATLAS Webinar Jan 2026

    [Topic] Precision Treatment and Translational Data Integration for Sarcomas and Rare Cancers

    [Date] 28 January 2026 


    [Opening Remarks] 0:00:00~

    Opening Remarks and Introduction of ATLAS

    Speaker: Dr. Yuta Sekino

    (General Manager, Asian Partnerships Office, National Cancer Center Hospital, Japan)


    [Lecture 1] 0:06:25～

    Precision radiotherapy for sarcomas and other rare cancers

    Speaker: Dr. Wong Ru Xin

    (Icon Cancer Centre, Singapore)


    [Lecture 2] 0:26:10~

    Data Integration & Multi-Institutional Efforts for Translational Sarcoma Research

    Speaker: Dr. Woo Xing Yi

    (A*STAR Bioinformatics Institute, Singapore)


    [Discussion] 0:52:13~

    Discussion

    Facilitator: Dr. Valerie Yang Shiwen

    (OncoCare Cancer Centre, Singapore)


  • Biliary Tract Cancer (BTC) | ATLAS Webinar Feb 2026

    [Topic] Biliary Tract Cancer (BTC)

    [Date] 26 February 2026 


    [Opening Remarks] 0:00:00~

    Opening Remarks and Introduction of ATLAS

    Speaker: Dr. Yuta Sekino

    (General Manager, Asian Partnerships Office, National Cancer Center Hospital, Japan)


    [Lecture 1] 0:08:40~

    Epidemiology and Clinical Practice of Biliary Tract Cancer in Southeast Asia

    Speaker: Dr. Thanachai Sanlung

    (Khon Kaen University, Thailand)


    [Lecture 2] 0:34:14~

    Current Standard and Future Perspectives of Immunotherapy for BTC

    Speaker: Dr. Do-Youn Oh

    (Seoul National University Hospital, South Korea)


    [Discussion] 1:13:44~ 

    Discussion

    Facilitator: Dr. Li-Tzong Chen

    (Kaohsiung Medical University Chung-Ho Memorial Hospital, Taiwan)

    Facilitator: Dr. Chigusa Morizane

    (National Cancer Center, Japan)


  • US & UK Clinical Trial Environment | ATLAS Webinar Mar 2026

    [Topic] US & UK Clinical Trial Environment

    [Date] 12 March 2026 


    [Opening Remarks] 0:00:00~

    Opening Remarks and Introduction of ATLAS

    Speaker: Dr. Yuta Sekino

    (General Manager, Asian Partnerships Office, National Cancer Center Hospital, Japan)


    [Lecture 1] 0:07:24~

    Navigating the US Clinical Trial Landscape: Operations, Regulations, and Financials

    Speaker: Ms. Tomomi Hata

    (National Cancer Center, Japan)


    [Lecture 2] 0:32:45~

    Clinical Research in the UK: The Centralized NHS Model and Evolving Regulatory Pathways

    Speaker: Ms. Celia St Clair

    (National Cancer Center, Japan)


    [Discussion] 1:02:35~ 

    Discussion

    Facilitator: Dr. Yuta Sekino

    (General Manager, Asian Partnerships Office, National Cancer Center Hospital, Japan)


  • Immunotherapy in treatment of locally advanced SCCHN - current paradigms and unmet needs | ATLAS Webinar Apr 2026

    [Topic] Immunotherapy in treatment of locally advanced SCCHN - current paradigms and unmet needs

    [Date] 24 April 2026 


    [Opening Remarks] 0:00:00~

    Opening Remarks and Introduction of ATLAS

    Speaker: Dr. Mitsumi Terada

    (Head, Asian Partnerships Section, Department of International Clinical Development, National Cancer Center Hospital, Japan)


    [Lecture 1] 0:05:41~

    Perioperative immunotherapy in head and neck cancer – hope or hype

    Speaker: Dr. Gopal Iyerw

    （National Cancer Centre, Singapore)


    [Lecture 2] 0:23:44~

    Current Status and Future Directions of Combination Therapy in HNSCC

    : Strategic Optimization in Locally-Advanced and Recurrent or Metastatic Disease 

    Speaker: Dr. Kao Hsiang Fong

    (National Taiwan University Hospital, Taiwan)


    [Discussion] 0:42:11~

    Discussion

    Facilitator: Dr. Mitsumi Terada

    (Head, Asian Partnerships Section, Department of International Clinical Development, National Cancer Center Hospital, Japan)